Goldman Sachs initiates coverage on Mamaearth with buy rating, stock jumps 5%

Goldman Sachs initiates coverage on Mamaearth with buy rating, stock jumps 5%

Global brokerage firm Goldman Sachs initiated coverage on Honasa Consumer (Mamaearth) with a ‘Buy’ rating and target price of Rs 570, which indicates an upside potential of 26% from the previous day’s closing price of Rs 451 apiece. Following the coverage initiation, shares of Mamaearth also jumped 5% to Rs 472 on BSE. In its … Read more

Kotak Equities initiates coverage on Mamaearth, cites 3 key differentiators

Kotak Equities initiates coverage on Mamaearth, cites 3 key differentiators

Domestic brokerage Kotak Institutional Equities has initiated coverage on Mamaearth’s parent company, Honasa Consumer with an ‘Add’ recommendation for a target price of Rs 450, an upside potential of 4% from the current levels. The brokerage states that it likes Honasa’s brand seeding/scaling and execution speed. A steady increase in repeat offtakes (conversion of experimentative … Read more

Companies flock to public markets as IPO fundraising jumps 19% to nearly Rs 62,000 cr in FY24

Companies flock to public markets as IPO fundraising jumps 19% to nearly Rs 62,000 cr in FY24

Buoyed by positive investor sentiment and listing gains, more companies have shown their appetite to raise funds through the primary market in FY24 compared to the previous year. About 76 companies accessed the public markets in FY24, raising nearly Rs 62,000 crore through mainboard IPOs. This is 19% higher than the Rs 52,116 crore mobilized … Read more

Hot Stocks: Brokerage view on Maruti Suzuki, ABB India, Mamaearth and Asian Paints

Hot Stocks: Brokerage view on Maruti Suzuki, ABB India, Mamaearth and Asian Paints

Brokerage firm Macquarie has a neutral rating on Maruti Suzuki, Axis Capital downgraded ABB India to reduce, CLSA has an underperform rating on Asian Paints and Citigroup initiated a buy on Honasa Consumer (Mamaearth). We have collated a list of recommendations from top brokerage firms from ETNow and other sources: Citigroup on Honasa Consumer: Buy| … Read more

We are focused on market share gain; almost 40% of our business comes from offline now: Honasa Consumer CFO

We are focused on market share gain; almost 40% of our business comes from offline now: Honasa Consumer CFO

Ramanpreet Sohi, CFO, Honasa Consumer, says “as a business and household brand, all our brands play in the mass premium, masstige categories. And this space is expected to grow at almost twice that of the mass segments in the country. Given that and how the whole online offline ecosystem is evolving, we are fairly uniquely … Read more

Mamaearth shares zoom 20% as investors find Q2 results toxin-free

Mamaearth shares zoom 20% as investors find Q2 results toxin-free

Shares of Honasa Consumer, which runs the Mamaearth brand of toxin-free products, on Thursday surged around 20% to touch a fresh peak of Rs 422.50 on BSE after the beauty and personal care products retailer reported 94% year-on-year (YoY) growth in Q2 profit. Driven by volume growth, Honasa’s quarterly revenue grew 21% YoY to Rs … Read more

Steep valuations haunt Mamaearth as stock sees tepid listing. Should you exit?

Steep valuations haunt Mamaearth as stock sees tepid listing. Should you exit?

The flat-to-muted listing of Mamaearth on Tuesday was in line with expectations as markets remained wary of high valuations of the company. The stock got listed at Rs 330 on NSE, up just 2% over the issue price. Post the debut, analysts advised investors to book profits notwithstanding the company’s strong brand presence in the … Read more

Roll out Covid vaccine without antibody testing: Dr K Srinath Reddy

Roll out Covid vaccine without antibody testing: Dr K Srinath Reddy

Against this backdrop, Dr Reddy endorsed Indian Council of Medical Research chief Dr Balaram Bhargav’s stand that vaccine coverage should target 60-70% of the population. Testing for presence of Covid-19 antibodies to determine whether a person should be prioritised for receiving the vaccine once this becomes available—the presence of antibodies, some have suggested, should push … Read more